



ReSearch Pharmaceutical Services, Inc. (RPS) Establishes Global Platform to Capitalize on Outsourced Clinical Trials

Fort Washington, PA (November 30, 2009) -- ReSearch Pharmaceutical Services, Inc. (RPS), a next generation contract research organization (CRO) and provider of integrated clinical development outsourcing solutions, today announced the completion of its global platform to provide advanced integrated CRO services across four continents.

RPS has positioned itself to capitalize on the growth of global clinical trials. PharmaVoice reported that up to 65% of FDA-regulated clinical trials in the next three years will be conducted outside of the United States, with Asia as one of the primary regions.

In creating its global platform, RPS recently incorporated its subsidiaries in more than 30 countries throughout the world, including Japan, Korea, Malaysia, Philippines, Singapore, Taiwan, and Thailand. The company also recently completed its acquisition of Paramax International (Beijing), Inc., a specialized contract research organization operating in China.

“Asia—and China in particular—is critically important to our clients,” noted Dan Perlman, Chairman and CEO of RPS. “Our acquisition of Paramax, along with the expansion of our unique service offerings throughout Asia provides deep local presence, which combined with our world-class platform enables us to serve our clients in a highly efficient manner. We have already begun to see significant revenue growth throughout the region.”

In the past 12 months, RPS has also strengthened its platform and local expertise in Europe through strategic acquisitions of CROs in France, Spain, and Germany.

“RPS offers comprehensive and customized solutions for the pharmaceutical industry,” commented Peter Yu, Managing Partner of Cartesian Capital Group and an RPS Board member. “We see an extraordinary need and demand for RPS’ offering around the world, especially as the outsourcing of clinical trials is growing. The Paramax acquisition and the recent global expansion of its platform will ensure that RPS clients receive the highest quality integrated CRO services wherever they need it.”

- more -

About ReSearch Pharmaceutical Services, Inc.

RPS is a next generation CRO and a leading provider of integrated clinical development outsourcing solutions to the bio-pharmaceutical industry. RPS provides services in connection with the design, initiation, and management of clinical trials programs that are required to obtain regulatory approval to market bio-pharmaceutical products. RPS' innovative business model combines the expertise of a traditional CRO with the ability to provide flexible outsourcing solutions that are fully integrated within RPS' clients' clinical drug development infrastructure.

About Cartesian Capital Group

Cartesian Capital Group LLC (www.cartesiangroup.com) is a global private equity firm, managing \$1.2 billion in capital. Founded in 2006 by Peter Yu, Cartesian has 23 professionals and offices in New York, Shanghai, São Paulo, Vienna, Warsaw, and Bucharest.

Contact:

John McInerney
Makovsky + Co.
212.508.9628
jmcinerney@makovsky.com

Travis Ferber
Makovsky + Co.
212.508.9653
tferber@makovsky.com

###